ROIV Roivant Sciences Ltd.

34.21USD-1.55%Mkt Cap: 24.71B $P/E: —

Roivant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines and technologies. Its clinical product candidates include IMVT-1402, a fully hu…

Key Statistics

Company
Market Cap24.71B USD
Enterprise Value22.06B USD
Revenue (TTM)7.53M USD
Gross Profit6.97M USD
Net Income (TTM)-299.77M USD
Revenue/Share0.01 USD
Last Price34.21 USD
Fiscal Year EndMar 2026
MR QuarterJun 2026
Employees721
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-19.92
PEG—
EV/EBITDA-16.21
EV/Revenue2928.36
P/S3280.76
P/B5.84
EPS (TTM)-0.53
EPS (Forward)-1.72
52W Range
14.9370% of range42.50
52W High42.50 USD
52W Low14.93 USD
Profitability
Gross Margin84.44%
Oper. Margin-25408.11%
EBITDA Margin0.00%
Profit Margin-3629.19%
ROE-6.62%
ROA-5.25%
Growth
Revenue Growth-33.50%
Earnings Growth—
Cash Flow & Leverage
Operating CF-750.35M USD
CapEx (TTM)8.21M USD
FCF Margin-14965.88%
FCF Yield-4.56%
Net Debt-3.73B USD
Net Debt/EBITDA2.75
Balance Sheet
Debt/Equity0.02
Current Ratio16.72
Quick Ratio13.62
Book Value/Sh5.86 USD
Cash/Share5.32 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)48.08 USD
Upside (mean)+40.6%
Target Range41.00 USD – 55.00 USD
41.00+40.6% to mean55.00
# Analysts12
Ownership
Shares Out.722.32M
Float581.94M
Insiders21.42%
Institutions78.41%
Short Interest
Short Ratio4.1d
Short % Float6.79%
Short % Out.5.01%
Shares Short36.18M
Short (prev mo.)30.60M
Technical
SMA 5036.64 (-6.6%)
SMA 20030.37 (+12.6%)
Beta1.10
S&P 52W Chg15.84%
Avg Vol (30d)7.70M
Avg Vol (10d)5.66M
Technical Indicators
RSI (14)37.5
MACD-0.5079
MACD Signal-0.0632
MACD Hist.-0.4448
BB Upper42.68 USD
BB Middle37.69 USD
BB Lower32.70 USD
BB Width26.49%
ATR (14)1.362 USD
Vol Ratio (20d)0.73x